Clinical trials: Minimal Disease, Residual
Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease
RATIONALE: Drugs used in chemotherapy, such as clofarabine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Trial name
- NCT00863434
- Testing
- clofarabine, cytarabine, filgrastim
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Washington
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission
Efficacy and Toxicity of Blinatumomab in the French ATU for Adult BCP-ALL R/R, or With MRD+ (FRENCH-CYTO)
The outcome of young adults (18-60 years) with ALL has been dramatically improved by the use of pediatric-inspired trials. About 60% of these young adult patients will be cured at 5 years.
- Trial name
- FRENCH-CYTO (NCT03751072)
- Where
- France
- Volunteers
- 92 people
- Sponsor
- Group for Research in Adult Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia
The researchers are doing this study to find out whether obecabtagene autoleucel (obe-cel) is an effective treatment for people with B-cell acute lymphoblastic leukemia (ALL) that is in complete remission (CR, meaning all signs…
- Trial name
- NCT07400029
- Testing
- Obecabtagene Autoleucel
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, Non Small Cell Lung Cancer
Minimal Residual Disease in Solid Malignancies
The IMRD study is a single-centre, prospective observational study which will investigate the rate of ctDNA (circulating tumor DNA) detection from the start of adjuvant therapy following curative-intent surgery.
- Conditions
- Breast Cancer, Non Small Cell Lung Cancer, Prostate Cancer, High Grade Serous Ovarian Cancer
- Trial name
- IMRD (NCT07268469)
- Testing
- ctDNA detection
- Volunteers
- 840 people
- Sponsor
- European Institute of Oncology
B Cell Precursor Acute Lymphoblastic Leukemia, Pediatric
NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALL
The goal of this clinical trial is to determine whether pediatric B-cell acute lymphoblastic leukemia (B-ALL) patients with negative deep minimal residue disease (MRD) can benefit from blinatumomab treatment.
- Conditions
- B Cell Precursor Acute Lymphoblastic Leukemia, Pediatric, Minimal Residual Disease, Next Generation Sequencing (NGS)
- Trial name
- NCT06763302
- Testing
- Blinatumomab
- Volunteers
- 1,220 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia
Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment
This phase II trial tests how well adding revumenib to usual treatment (blinatumomab) compared to usual treatment alone works in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) or acute leukemia with ambiguous…
- Conditions
- Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia
- Trial name
- NCT07636564
- Testing
- Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration
- Volunteers
- 90 people
- Sponsor
- SWOG Cancer Research Network
Lung Cancer
CLEAR-Lung III: Circulating Tumor DNA-Guided Consolidation Chemotherapy and Immunotherapy
CLEAR LUNG-III is a single-arm, phase II study evaluating a circulating tumor DNA (ctDNA)-guided treatment strategy in patients with unresectable stage III non-small cell lung cancer who have completed definitive chemoradiation…
- Trial name
- NCT07858253
- Testing
- Consolidation Chemotherapy
- Volunteers
- 43 people
- Sponsor
- Anusha Chidharla, MD
Medulloblastoma, Medulloblastoma, Childhood
Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease
This is a Phase 1/Phase 2 study assessing liothyronine (L-T3) immunotherapy and in combination with standard chemotherapy (bevacizumab, irinotecan and temozolomide (BIT)) in children and young adults with medulloblastoma that is…
- Conditions
- Medulloblastoma, Medulloblastoma, Childhood, Medulloblastoma Recurrent
- Trial name
- PNOC044 (NCT07346157)
- Testing
- Liothyronine (L-T3), Bevacizumab, Irinotecan
- Where
- 3 sites in United States
- Volunteers
- 69 people
- Sponsor
- Sabine Mueller, MD, PhD
Colorectal Cancer, Minimal Residual Disease
Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)
To find the highest and/or recommended dose of TROP2-CAR-NK cells combined with cetuximab in participants with MRD CRC.
- Trial name
- NCT06358430
- Testing
- Fludarabine Phosphate, Cyclophosphamide, Cetuximab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia, Measurable Residual Disease
Motixafortide for MRD Sensitization in AML
This is a pilot phase I study evaluating the effect of motixafortide on determination of measurable residual disease (MRD) level in patients with acute myeloid leukemia (AML) who have completed induction treatment.
- Trial name
- NCT07392970
- Testing
- Motixafortide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Washington University School of Medicine
Hairy Cell Leukemia
Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia
Background: Hairy cell leukemia (HCL) is highly responsive to but not curable by cladribine (CdA). HCL responds to rituximab, which is not yet standard therapy for HCL.
- Trial name
- NCT00923013
- Testing
- Cladribine, Rituximab, BMbx
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- National Cancer Institute (NCI)
Stem Cell Transplant Complications, Leukemia, Myeloid, Acute
Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT
Allogeneic haematopoietic stem cell transplantation (allo-HSCT) remains one of the currently available curative therapies for acute leukemia (AL). Leukemia relapse is one of the mainly causes of transplant failure.
- Conditions
- Stem Cell Transplant Complications, Leukemia, Myeloid, Acute, Leukemia Relapse
- Trial name
- NCT03793517
- Testing
- Decitabine, mBU/CY and ATG, mBU/CY
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Peking University People's Hospital
Breast Cancer, TNBC - Triple-Negative Breast Cancer
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
For patients with breast cancer, it's important to find any remaining cancer cells after they've had their main treatment. Even a few cells, called minimal residual disease (MRD), can lead to the cancer coming back later.
- Conditions
- Breast Cancer, TNBC - Triple-Negative Breast Cancer, HR Positive/HER-2 Negative Breast Cancer, HER2 + Breast Cancer
- Trial name
- GEMINI Breast (NCT07211178)
- Testing
- There are no interventions in this observational study.
- Where
- 16 sites in United States
- Volunteers
- 900 people
- Sponsor
- Tempus AI
Hepatocellular Carcinoma Resectable, Surgery
Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma
The aim of this study was to compare the accuracy of ctDNA-MRD longitudinal surveillance model and internationally accepted pathological MVI results in predicting recurrence after radical hepatectomy.
- Conditions
- Hepatocellular Carcinoma Resectable, Surgery, Recurrence
- Trial name
- NCT06449846
- Testing
- circulating tumor cell DNA detection
- Where
- 4 sites in China
- Volunteers
- 152 people
- Sponsor
- Zhujiang Hospital
Acute Myeloid Leukemia, Myelodysplastic Syndromes
PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS
This is a first-in-human dose escalation/dose expansion study to evaluate the safety and identify the best dose of modified immune cells, PRGN-3006 (autologous chimeric antigen receptor (CAR) T cells), in adult patients with…
- Trial name
- NCT03927261
- Testing
- PRGN-3006 T Cells
- Where
- 2 sites in United States
- Volunteers
- 88 people
- Sponsor
- Precigen, Inc
Breast Cancer, Measurable Residual Disease
Exploratory Research on Constructing a Computational Biological Model Based on NGS for MRD After Breast Cancer Surgery
This study will include 80 subjects after radical breast cancer resection, collect blood samples of the above subjects, observe and quantify the characteristic changes of cfDNA in the blood of breast cancer subjects after…
- Trial name
- NCT06595966
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Myelodysplastic Syndromes, Acute Myeloid Leukemia With Myelodysplasia Related Disease and < 30% Blasts
A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS
The goal of this interventional study is to evaluate if pre-emptive intervention using Azacitidine and / or donor lymphocytes or tapering of immune suppression in measurable residual disease (MRD) positive subjects can prevent…
- Conditions
- Myelodysplastic Syndromes, Acute Myeloid Leukemia With Myelodysplasia Related Disease and < 30% Blasts, Mixed Myelodysplastic/Myeloproliferative Disease
- Trial name
- NCT05788679
- Testing
- Azacitidine, Donor lymphocytes, Tapering of immune suppression
- Where
- Sweden
- Volunteers
- 200 people
- Sponsor
- Karolinska University Hospital
Non Hodgkin Lymphoma
Assessment of the Minimal Residual Disease in DLBCL From Cell-free Circulating DNA by NGS
This is a prospective descriptive monocentric study whose purpose is to describe the clonal evolution of the mutational pattern in cfDNA of a cohort of patients with Diffuse Large B-Cell Non-Hodgkin Lymphomas (DLBCL) before…
- Trial name
- LymphoSeq (NCT02339805)
- Testing
- next generation sequencing, Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Henri Becquerel
Uterine Cervical Neoplasms
Detection of Minimal Residual Disease Based on HPV ctDNA in Cervical Cancer
In this study, a large-scale cohort of cervical cancer patients was established in multiple centers. Minimal residual disease(MRD) was assessed by ddPCR detection of HPV E7 gene ctDNA to assess tumor burden and predict the risk…
- Trial name
- NCT05531981
- Testing
- detect HPV E7 ctDNA
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Peking Union Medical College Hospital
Minimal Residual Disease, Pancreatic Cancer Resectable
Evaluate the Clinical Feasibility of a Novel Neoantigen-Reactive CD8+ T Cell (NART) Detection Technology for Postoperative MRD Surveillance of Pancreatic Cancer
The goal of this observational study is to learn about the diagnostic performance of a novel Neoantigen-Reactive CD8+ T cell (NART) technology detecting minimal residual disease (MRD) in postoperative surveillance of pancreatic…
- Trial name
- NCT06941987
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Shanghai Zhongshan Hospital